Dexamethasone erythrocyte-encapsulated - EryDel

Drug Profile

Dexamethasone erythrocyte-encapsulated - EryDel

Alternative Names: Dexa 21-P – EryDel; Ery-Dex

Latest Information Update: 14 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EryDel
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ataxia telangiectasia; Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ataxia telangiectasia
  • Discontinued Chronic obstructive pulmonary disease; Crohn's disease; Cystic fibrosis; Ulcerative colitis

Most Recent Events

  • 06 Mar 2017 Phase-III clinical trials in Ataxia telangiectasia (In children, In adolescents, In adults, In the elderly) in Tunisia, India, Australia, Israel, USA (IV)
  • 03 Feb 2016 EryDel completes a phase II trial in Ataxia telangiectasia in Italy before February 2016
  • 03 Aug 2015 Phase II development for Ataxia telangiectasia is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top